What the Updated Synthesis Actually Found
This chapter interprets the updated quantitative evidence on coffee, caffeine, and cardiovascular outcomes. The focus is the pattern produced when many studies are pooled—not just whether one headline points up or down. By the end, the reader should be able to describe what the review found for each major outcome and understand why those estimates do not add up to a single verdict about coffee.
What the review compared
The updated systematic review searched for studies published from 2000 through December 2025 and included 38 studies with 2,856,002 participants. The final set consisted of 33 cohort studies and five case-control studies. A cohort study follows a group over time and compares later outcomes across exposure patterns; a case-control study starts with people who have an outcome and compares their prior exposures with those of people who do not. Both designs can reveal important associations, but neither is the same as randomly assigning people to drink a fixed amount of coffee for years.
The review separated coffee consumption from caffeine intake where the underlying studies allowed it, and it separated cardiovascular outcomes rather than combining them into one composite measure. The coffee analyses addressed coronary heart disease, myocardial infarction, stroke, heart failure, and arrhythmias. The caffeine analyses also examined cardiovascular mortality in the general population and in people with hypertension, diabetes, or prediabetes, as well as atrial fibrillation. This separation is central: the question “What is the relationship between coffee and MI?” is not the same as “What is the relationship between caffeine and cardiovascular death among people with hypertension?”
Most pooled comparisons contrasted the highest and lowest intake categories within each study. That wording sounds more standardized than it is. One study’s highest category might begin at two cups a day; another’s might begin at four, six, or more. The categories could also represent different kinds of coffee, different serving sizes, or different ways of estimating caffeine. The meta-analysis can combine the direction and size of those study-specific associations, but it cannot turn them into one universal dose comparison.
The results are reported using measures such as the hazard ratio and the odds ratio. A hazard ratio, or HR, compares the rate at which an outcome occurs over the follow-up period between groups. An odds ratio, or OR, compares the odds of an outcome between groups, often in a case-control or event analysis. A value below 1 points toward a lower observed rate or odds in the higher-exposure group; a value above 1 points toward a higher one. Neither measure, by itself, tells a person how many events would occur in absolute terms, and an HR and an OR should not be treated as interchangeable percentages.
The review also reports p-values, which summarize how compatible the observed result is with a specified no-association model under the study’s assumptions. A small p-value can make a result statistically distinguishable from that model, but it does not measure clinical importance, prove causation, or show that the exposure caused the difference. Conversely, a nonsignificant result does not prove that every dose, subgroup, or preparation has exactly no effect. The direction, magnitude, comparator, uncertainty, and design have to be read together.